Brief: Akari Presents Results From Two Preclinical Development Programs Of Long-Acting Pas-Nomacopan

Akari Therapeutics

09/05/2022 12:37

May 9 (Reuters) - Akari Therapeutics PLC  AKTX.O :
    * AKARI PRESENTS RESULTS FROM TWO PRECLINICAL DEVELOPMENT
PROGRAMS
OF LONG-ACTING PAS-NOMACOPAN IN GEOGRAPHIC ATROPHY (GA) DRY
AGE-RELATED MACULAR DEGENERATION AND NOMACOPAN IN EXPERIMENTAL
IMMUNE-MEDIATED CONJUNCTIVAL DISEASE (EIC)

Source text for Eikon:  ID:nGNX2WvqnG 
Further company coverage:  AKTX.O 

 ((Reuters.Briefs@thomsonreuters.com;))